Improving Good Practice: A Survey of Unlicensed and Off-Label Drug Use in a General Hospital in China

Therapeutic Innovation & Regulatory Science - Tập 47 - Trang 397-404 - 2013
Hanbin Wu1, Gao Wu2
1Shanghai East Hospital Tongji University, School of Medicine Shanghai China
2Department of Pharmacy, The 411st Hospital of PLA, Shanghai, China

Tóm tắt

Off-label and unlicensed drug use is common in Europe and the US; however, information about this issue in China is limited. To determine the scope and scale of off-label and unlicensed drug use in general hospitals in Shanghai, China, and to evaluate the varying levels of supporting evidence. A total of 493 cases of discharge history were randomly sampled. Off-label uses were defined according to package inserts, the China Pharmacopeia Clinical Medication Notice (2010), and New Pharmacology (16th edition). All drugs administered were assessed to determine whether their use was unlicensed and off-label. There were 459 cases (93.10%) of off-label drug use, and 47.64% of total therapeutic drugs prescribed were off-label. Of these cases, 8.72% of patients received 1 off-label drug, and 9.94% of patients received 2 off-label drugs. Use of multiple off-label medications per patient was also common, and the percentage of patients receiving 3, 4, 5, 6, 7, 8, 9, and ≥10 medications was 9.74%, 9.74%, 8.72%, 7.91%, 12.58%, 7.10%, 5.88%, and 12.78%, respectively. Categories of off-label drugs used most frequently were vitamins, cardiovascular drugs, and gastroenteric drugs. The most common off-label use was that the indication for which a drug was prescribed was not approved (83.49%); other off-label uses involved disregard for contraindications and drug incompatibility (6.37%), dose exceeding approved amount (4.76%), unapproved route of administration (4.65%), and unapproved dosing intervals (0.73%). Vitamins and nutritional supplements are the drugs most frequently prescribed off-label, while off-label use of vasodilators, lipid-lowering drugs, and adjuvant therapy medications for cardiovascular and cerebrovascular conditions is also common. Unlicensed and off-label prescribing of drugs may be common in China.

Tài liệu tham khảo

Jansen RM. The off-label use of medication in South Africa—what about some information for medical practitioners? S Afr Med J. 2009,99:438–439.

Landow L. Off-label use of approved drugs. Chest. 1999;116:589–591.

Gazarian M, Kelly M, McPhee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness. Med J Aust. 2006;185:544–548.

Allen R, O’Brien BM. Uses of misoprostol in obstetrics and gynecology. Rev Obstet Gynecol. 2009;2:159–168.

Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ. 2000;320:79–82.

’t Jong GW, Eland IA, Sturkenboom MC, et al. Unlicensed and off-label prescription of respiratory drugs to children. Eur Respir J. 2004;23:310–313.

O’Donnell CP, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics. 2002;110:e52.

Shah SS, Hall M, Goodman DM, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med. 2007;161:282–290.

Chi L, Zhang X. Survey and analysis of drug use beyond dispensatory in pediatrics. Chin J Pharmacoepidemiol. 2011;20:351–353.

Zeng X, Zhou B. Survey and analysis on a written description of the pediatric drug external use of pediatric in-patient department. China Medical Herald. 2011;8:113–114.

State Pharmacopoeia Commission. The China Pharmacopeia Clinical Medication Notice. Beijing: China Medical Science and Technology Press; 2010.

Xinqian C, Youyu J, Guang T. New Pharmacology. 16th ed. Beijing: People’s Health Publishing House; 2007.

Yi Z, Zhai S, Huang S, et al. Off-label prescriptions for adult neurological patients: a pilot survey in China. Int J Clin Pharm. 2012;34:81–87.

Yang G, Wan X, Wu X. Selection of acid inhibitors for patients with critical condition. Journal of Dalian Medical University. 2010;32:441–443.

National Medical Journal of China Editorial Board. Stress ulcer prevention suggestions. National Medical Journal of China. 2002;82:1000–1001.

Sun H, Wang C, Li Y. Analysis on utilization of liver-protective medicines in our hospital during 2004–2008. China Pharmacy. 2010;21:494–496.

Xu H, Yang Y. Clinical progression on pleiotropic effects of statins. Advances in Cardiovascular Diseases. 2011;32:649–652.

Zhang J, Huang Y. Group of the China Quality Evaluation of Stroke Care and Treatment. Treatment of acute ischemic stroke in China. Chin J Neurol. 2009;42:223–228.

Cerebrovascular Disease Study Group With Acute Ischemic Stroke Treatment Guidelines Writing Group of Chinese Society of Neuropathy. Guidelines for the diagnosis and treatment of acute ischemic stroke. Chin J Neurol. 2010;43:146–153.

Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42: 227–276.

Zhu Y, Liu Q. Influence of Shanghai Guiding Principles of Clinical Use of Antibiotics Implementing Rules (Trial) on prophylactic use of drugs in patients underwent general surgery operation. China Pharmacy. 2010; 21:2806–2809.

Hua G, He T, Zhang Y. Clinical application of antibiotics in 2009. Chinese Journal of Nosocomiology. 2011;21:3020–3022.

Yang W, Xu Y, Sun L, et al. Compatible stabilities of insulin injection mixed with five kinds of injection in 5% glucose injection. Chinese Journal of Clinical Pharmacy. 2011;20:92–95.

Zhang C, Fan Q, Lu H, et al. Investigation the stability of compatibility of insulin in glucose and xiangdan solution for injection by HPLC. China Pharmacist. 2008;11:1299–1300.

Tian Y, Li Pa, Li C. Review of the incompatibility of traditional Chinese medicine injection in Clinical. Chinese Journal of Pharmacovigilance. 2010;7:105–108.

Rowland D, McMahon CG, Abdo C, et al. Disorders of orgasm and ejaculation in men. J Sex Med. 2010;7:1668–1686.

Zhang Y, Liu S, Zhu G, et al. Clinical study of Sildenafil for the treatment of pulmonary hypertension. Journal of Cardiovascular and Pulmonary Diseases. 2011;30:20–24.

Liao G. Exploration of the management of antibiotics use in the clinic. China Pharmacy. 2011;22:2406–2408.

Xu R, Zhang S, Chen J. Suggestion and pondering for the registration system of medical representatives. China Pharmacy. 2007;18:241–243.

Zheng J. Doctors’ incentive and separation mechanism design. Chinese Hospitals. 2010;14:42–45.

Zhou Y, Li K, Huang J, et al. Analysis on unharmonious factors influencing hospital and patient relationship and their countermeasures. Chinese Hospitals. 2011;15:58–61.

Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Arch Intern Med. 2006;166:1021–1026.

Jansen RM, Gouws C. Clinical, legal and ethical implications of the intra-ocular (off-label) use of bevacizumab (Avastin)—a South African perspective. S Afr Med J. 2009;99:446–449.

Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

Stafford RS. Regulating off-label drug use—rethinking the role of the FDA. N Engl J Med. 2008;358:1427–1429.

People’s Republic of China, Ministry of Health. The Ministry of Health Prescription Management Policy, May 1, 2007 [in Chinese]. http://www.gov.cn/flfg/2007-03/13/content_549406.htm.

People’s Republic of China, Ministry of Health. Hospital Prescription Comment Management Practices (Trial), February 10, 2010 [in Chinese]. http://www.gov.cn/gzdt/2010-03/04/content_1547080.htm.

Chen X, Huang Z, Hou L, et al. Expert consensus document on drug off-label use. Pharmacy Today. 2010;20:1–3.

Toscani F, Di Giulio P, Campi R, et al. Off-label prescriptions in Italian hospices: a national survey. J Pain Symptom Manage. 2009;38:365–371.

Largent EA, Miller FG, Pearson SD. Going off-label without venturing off-course: evidence and ethical off-label prescribing. Arch Intern Med. 2009;169:1745–1747.

Thông tin
Thông tin xuất bản

Therapeutic Innovation & Regulatory Science

Tập 47

397-404

Thông tin tác giả